Processa Pharmaceuticals, Inc. (PCSA) — Financial statements
Income statement, balance sheet, and cash flow for Processa Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00↓100.0% | 0.87 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00↑100.0% | -0.87 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 8↑7.4% | 7↑25.3% | 6↓49.5% | 11↑67.1% | 7 | |
| General & Administrative Expenses | 6↑29.2% | 5↓15.5% | 6↓35.4% | 9↑86.9% | 5 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 6↑29.2% | 5↓15.5% | 6↓35.4% | 9↑86.9% | 5 | |
| Other Expenses | 0.00 | 0.00 | 0.00↓100.0% | 7↑1182.8% | 0.57 | |
| Operating Expenses | 14↑16.1% | 12↑5.2% | 11↓58.4% | 28↑126.9% | 12 | |
| Total Costs & Expenses | 14↑16.1% | 12↑5.2% | 11↓58.4% | 28↑126.9% | 12 | |
| Operating Results | ||||||
| Operating Income | -14↓16.1% | -12↓5.2% | -11↑58.4% | -28↓126.9% | -12 | |
| Depreciation & Amortization | 0.00↑54.0% | 0.00↑252.3% | 0.00↓100.0% | 0.79↓0.3% | 0.79 | |
| EBITDA | -14↓16.1% | -12↓5.2% | -11↑41.2% | -19↓80.7% | -11 | |
| EBIT | -14↓16.1% | -12↓5.2% | -11↑43.4% | -20↓75.1% | -12 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.11↓45.6% | 0.20↓40.1% | 0.34↑231.6% | 0.10↑770.4% | 0.01 | |
| Interest Income | 0.11↓45.6% | 0.20↓40.1% | 0.34↑231.6% | 0.10↑744.1% | 0.01 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00↑100.0% | -7↓1182.8% | -0.57 | |
| Other Income / Expenses | 0.42↑111.2% | 0.20↓40.1% | 0.34↑231.6% | 0.10↓42.3% | 0.18 | |
| Income Before Tax | -14↓14.5% | -12↓6.6% | -11↑59.4% | -27↓129.3% | -12 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -0.53 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -14↓14.5% | -12↓6.6% | -11↑59.4% | -27↓140.0% | -11 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -14↓14.5% | -12↓6.6% | -11↑59.4% | -27↓140.0% | -11 | |
| Bottom-Line Net Income | -14↓14.5% | -12↓6.6% | -11↑59.4% | -27↓140.0% | -11 | |
| EPS (Basic) | -10.36↑89.3% | -96.75↑54.4% | -212.00↑75.1% | -851.19↓128.2% | -373.00 | |
| EPS (Diluted) | -10.36↑89.3% | -96.75↑54.4% | -212.00↑75.1% | -851.19↓128.2% | -373.00 | |
| Weighted Average Shares | 1↑969.7% | 0.12↑133.3% | 0.05↑62.8% | 0.03↑5.2% | 0.03 | |
| Weighted Average Diluted Shares | 1↑969.7% | 0.12↑133.3% | 0.05↑62.8% | 0.03↑5.2% | 0.03 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.